Accustem Sciences (ACUT) Cash from Financing Activities (2022 - 2026)
Accustem Sciences (ACUT) posted quarterly Cash from Financing Activities of $372454.0 for Q1 2026, up 15.84% year-over-year from $321517.0 in Q1 2025, and up 1732.14% quarter-over-quarter from -$22820.0 in Q4 2025.
Accustem Sciences (ACUT) Cash from Financing Activities (2022 - 2026) Analysis & Trends
Accustem Sciences (ACUT) has reported Cash from Financing Activities for 5 consecutive years, with $372454.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 15.84% year-over-year to $372454.0; the TTM figure through Mar 2026 stood at $910208.0 (up 22.36% YoY), while the FY2025 annual figure was $859271.0, up 32.68% from the prior year.
- Cash from Financing Activities improved to $372454.0 in Q1 2026 per ACUT's latest filing, from -$22820.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $2.9 million in Q1 2022 and bottomed at -$259803.0 in Q2 2022.
- Historically, Cash from Financing Activities has averaged $313737.2 across 5 years, with a median of $225243.0 in 2024.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities surged 911.17% — and 2024, when it plunged 113.22%.
- Accustem Sciences' Cash from Financing Activities stood at $24279.0 in 2022, then soared by 911.17% to $245502.0 in 2023, then slumped by 113.22% to -$32447.0 in 2024, then climbed by 29.67% to -$22820.0 in 2025, then surged by 1732.14% to $372454.0 in 2026.
- Business Quant data shows ACUT's Cash from Financing Activities at $372454.0 in Q1 2026, -$22820.0 in Q4 2025, and $587181.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Accustem Sciences | 2.57 Mn | 2.56 Mn | - | 249,571.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 372,454.00 |
| Mar 31, 2026 | 372,454.00 |
| Dec 31, 2025 | -22,820.00 |
| Dec 31, 2025 | -22,820.00 |
| Sep 30, 2025 | 587,181.00 |
| Sep 30, 2025 | 587,181.00 |
| Jun 30, 2025 | -26,607.00 |
| Jun 30, 2025 | -26,607.00 |
| Mar 31, 2025 | 321,517.00 |
| Mar 31, 2025 | 321,517.00 |
| Dec 31, 2024 | -32,447.00 |
| Dec 31, 2024 | -32,447.00 |
| Sep 30, 2024 | 208,955.00 |
| Sep 30, 2024 | 208,955.00 |
| Jun 30, 2024 | 245,881.00 |
| Jun 30, 2024 | 245,881.00 |
| Mar 31, 2024 | 225,243.00 |
| Mar 31, 2024 | 225,243.00 |
| Dec 31, 2023 | 245,502.00 |
| Dec 31, 2023 | 245,502.00 |